Vaccine-Derived Polioviruses
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
The attenuated oral poliovirus vaccine (OPV) has many properties favoring its use in polio eradication: ease of administration, efficient induction of intestinal immunity, induction of durable humoral immunity, and low cost. Despite these advantages, OPV has the disadvantage of genetic instability, resulting in rare and sporadic cases of vaccine-associated paralytic poliomyelitis (VAPP) and the emergence of genetically divergent vaccine-derived polioviruses (VDPVs). Whereas VAPP is an adverse event following exposure to OPV, VDPVs are polioviruses whose genetic properties indicate prolonged replication or transmission. Three categories of VDPVs are recognized: (1) circulating VDPVs (cVDPVs) from outbreaks in settings of low OPV coverage, (2) immunodeficiency-associated VDPVs (iVDPVs) from individuals with primary immunodeficiencies, and (3) ambiguous VDPVs (aVDPVs), which cannot be definitively assigned to either of the first 2 categories. Because most VDPVs are type 2, the World Health Organization's plans call for coordinated worldwide replacement of trivalent OPV with bivalent OPV containing poliovirus types 1 and 3.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bulletin of the World Health Organization
Frick, K. D., Lynch, M. C., West, S. K., Muñoz, B., & Mkocha, H. A. (2003) · Bulletin of the World Health Organization · Cited by 2,660
VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION
Kew, O. M., Sutter, R. W., de Gourville, E. M., Dowdle, W. R., & Pallansch, M. A. (2005) · Annual Review of Microbiology · doi:10.1146/annurev.micro.58.030603.123625 · Cited by 703
Self-citationKew, O., Morris-Glasgow, V., Landaverde, M., Burns, C., Shaw, J., Garib, Z., André, J., Blackman, E., Freeman, C. J., Jorba, J., et al. (2002) · Science · doi:10.1126/science.1068284 · Cited by 600 · cited 3×
“1% of reported cases) were associated with the outbreaks in Hispaniola in 2000–2001 and Indonesia in 2005 [8, 37].”
BackgroundSelf-citationFrom Emergence to Eradication: The Epidemiology of Poliomyelitis Deconstructed
Nathanson, N., & Kew, O. M. (2010) · American Journal of Epidemiology · doi:10.1093/aje/kwq320 · Cited by 404
Self-citationFine, P. E. M., & Carneiro, I. A. M. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009924 · Cited by 247
Brown, B., Oberste, M. S., Maher, K., & Pallansch, M. A. (2003) · Journal of Virology · doi:10.1128/jvi.77.16.8973-8984.2003 · Cited by 238
Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993
Yang, C.-F., Naguib, T., Yang, S.-J., Nasr, E., Jorba, J., Ahmed, N., Campagnoli, R., van der Avoort, H., Shimizu, H., Yoneyama, T., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.15.8366-8377.2003 · Cited by 233
Self-citationProlonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient
Kew, O. M., Sutter, R. W., Nottay, B. K., McDonough, M. J., Prevots, D. R., Quick, L., & Pallansch, M. A. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.10.2893-2899.1998 · Cited by 213 · cited 4×
“However, individuals infected with iVDPVs are at risk of developing paralytic poliomyelitis [6, 7, 25] and may infect others, presenting the potential risk of outbreaks [26].”
BackgroundInfluentialSelf-citationVaccine Policy Changes and Epidemiology of Poliomyelitis in the United States
Alexander, L. N. (2004) · JAMA · doi:10.1001/jama.292.14.1696 · Cited by 203
Kilpatrick, D. R., Yang, C.-F., Ching, K., Vincent, A., Iber, J., Campagnoli, R., Mandelbaum, M., De, L., Yang, S.-J., Nix, A., et al. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00702-09 · Cited by 187
Self-citationCalibration of multiple poliovirus molecular clocks covering an extended evolutionary range
Jorba, J., Campagnoli, R., De, L., & Kew, O. (2008) · Journal of Virology · doi:10.1128/jvi.02354-07 · Cited by 177
Self-citationAlexander, J. P., Gary, H. E., & Pallansch, M. A. (1997) · Journal of Infectious Diseases · doi:10.1093/infdis/175.supplement_1.s176 · Cited by 170 · cited 1×
“A small number of individuals with PIDs who are exposed to OPV may have prolonged infections lasting >6 months [4] and excrete virus derived from the vaccine for periods substantially longer than the 4–6 weeks typical for immunologically normal OPV recipients [17].”
BackgroundSutter, R. W., Kew, O. M., & Cochi, S. L. (2008) · Vaccines · doi:10.1016/b978-1-4160-3611-1.50030-1 · Cited by 167
Self-citationMacLennan, C., Dunn, G., Huissoon, A. P., Kumararatne, D. S., Martin, J., O'Leary, P., Thompson, R. A., Osman, H., Wood, P., Minor, P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16150-3 · Cited by 162
Martín, J., Dunn, G., Hull, R., Patel, V., & Minor, P. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.7.3001-3010.2000 · Cited by 160 · cited 2×
“Key distinguishing features of iVDPV isolates may include (1) heterogeneity at sites of nucleotide variability within a serotype (indicative of mixed virus populations) [6, 49, 50], (2) nonrecombinant or vaccine/vaccine-recombinant genomes [4, 10], (3) more-extensive antigenic variability than typically observed with…”
Background“A Rose is a Rose is a Rose,” but CVID is Not CVID
Yong, P. F. K., Thaventhiran, J. E. D., & Grimbacher, B. (2011) · Advances in immunology · doi:10.1016/b978-0-12-385991-4.00002-7 · Cited by 160
Burns, C. C., Shaw, J., Jorba, J., Bukbuk, D., Adu, F., Gumede, N., Pate, M. A., Abanida, E. A., Gasasira, A., Iber, J., et al. (2013) · Journal of Virology · doi:10.1128/jvi.02954-12 · Cited by 153 · cited 9×
“Genetic analysis resolved the outbreak into >20 independent VDPV2 emergences that occurred since 2004, at least 7 of which established circulating lineages [19, 42].”
BackgroundInfluentialSelf-citationCirculation of type 1 vaccine-derived poliovirus in the philippines in 2001
Shimizu, H., Thorley, B., Paladin, F. J., Brussen, K. A., Stambos, V., Yuen, L., Utama, A., Tano, Y., Arita, M., Yoshida, H., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.24.13512-13521.2004 · Cited by 146
Self-citationGenetic basis of attenuation of the Sabin type-2 vaccine strain of poliovirus in primates.
Macadam, A. J., Pollard, S. R., Ferguson, G., Skuce, R., Wood, D., Almond, J. W., & Minor, P. D. (1993) · Virology · doi:10.1006/viro.1993.1003 · Cited by 139
Recombinant Vaccine–Derived Poliovirus in Madagascar
Rousset, D., Rakoto-Andrianarivelo, M., Razafindratsimandresy, R., Randriamanalina, B., Guillot, S., Balanant, J., Mauclère, P., & Delpeyroux, F. (2003) · Emerging Infectious Diseases · doi:10.3201/eid0907.020692 · Cited by 138 · cited 2×
“The first reports of highly divergent iVDPVs [6, 7] and cVDPVs [8, 9, 32] appeared within a few years of each other, prompting speculation that cVDPV outbreaks may be triggered by iVDPV”
BackgroundImplications of a circulating vaccine-derived poliovirus in Nigeria
Jenkins, H. E., Aylward, R. B., Gasasira, A., Donnelly, C. A., Mwanza, M., Corander, J., Garnier, S., Chauvin, C., Abanida, E., Pate, M. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0910074 · Cited by 131
Bellmunt, A., May, G., Zell, R., Pring-Åkerblom, P., Verhagen, W., & Heim, A. (1999) · Virology · doi:10.1006/viro.1999.0003 · Cited by 128 · cited 3×
“However, individuals infected with iVDPVs are at risk of developing paralytic poliomyelitis [6, 7, 25] and may infect others, presenting the potential risk of outbreaks [26].”
BackgroundMacadam, A. J., Arnold, C., Howlett, J., John, A., Marsden, S., Taffs, F., Reeve, P., Hamada, N., Wareham, K., Almond, J., et al. (1989) · Virology · doi:10.1016/0042-6822(89)90183-9 · Cited by 125
Minor, P. D., & Dunn, G. (1988) · Journal of General Virology · doi:10.1099/0022-1317-69-5-1091 · Cited by 120
Wassilak, S., Pate, M. A., Wannemuehler, K., Jenks, J., Burns, C., Chenoweth, P., Abanida, E. A., Adu, F., Baba, M., Gasasira, A., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiq140 · Cited by 120
Self-citationLiu, H.-M., Zheng, D.-P., Zhang, L.-B., Oberste, M. S., Pallansch, M. A., & Kew, O. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.23.11153-11161.2000 · Cited by 119 · cited 1×
“Genetic lineages, typical of wild poliovirus circulation [18, 35], represent chains of transmission that may be inferred directly”
BackgroundSelf-citationJegouic, S., Joffret, M.-L., Blanchard, C., Riquet, F. B., Perret, C., Pelletier, I., Colbere-Garapin, F., Rakoto-Andrianarivelo, M., & Delpeyroux, F. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000412 · Cited by 116
Khetsuriani, N., Prevots, D. R., Quick, L., Elder, M. E., Pallansch, M., Kew, O., & Sutter, R. W. (2003) · The Journal of Infectious Diseases · doi:10.1086/379791 · Cited by 110
Self-citationParalytic Disease Associated With Oral Polio Vaccines
Henderson, D. A., Witte, J. J., Morris, L., & Langmuir, A. D. (1964) · JAMA · doi:10.1001/jama.1964.03070140047006 · Cited by 108
Halsey, N. A., Pinto, J. A., Espinosa-Rosales, F. J., Faure-Fontenla, M. A., da Silva, E., Khan, A. J., WEBSTER, A. D. B., Minor, P. D., Dunn, G., Asturias, E. J., et al. (2004) · Europe PMC (PubMed Central) · Cited by 106
Self-citationYang, C.-F., Chen, H.-Y., Jorba, J., Sun, H.-C., Yang, S.-J., Lee, H.-C., Huang, Y.-C., Lin, T.-Y., Chen, P.-J., Shimizu, H., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.20.12623-12634.2005 · Cited by 106
Self-citationTebbens, R. J. D., Pallansch, M. A., Kim, J., Burns, C. C., Kew, O. M., Oberste, M. S., Diop, O. M., Wassilak, S. G. F., Cochi, S. L., & Thompson, K. M. (2013) · Risk Analysis · doi:10.1111/risa.12022 · Cited by 105
Self-citationBlomqvist, S., Savolainen, C., Laine, P., Hirttiö, P., Lamminsalo, E., Penttilä, E., Jöks, S., Roivainen, M., & Hovi, T. (2004) · Journal of Virology · doi:10.1128/jvi.78.9.4876-4883.2004 · Cited by 104
Reemergence of recombinant vaccine–derived poliovirus outbreak in Madagascar.
Rakoto‐Andrianarivelo, M., Gumede, N., Jegouic, S., Balanant, J., Andriamamonjy, S. N., Rabemanantsoa, S., Birmingham, M., Randriamanalina, B., Nkolomoni, L., Venter, M., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/587694 · Cited by 100
Transmission of Imported Vaccine‐Derived Poliovirus in an Undervaccinated Community in Minnesota
Alexander, J. P., Ehresmann, K., Seward, J., Wax, G., Harriman, K., Fuller, S., Cebelinski, E. A., Chen, Q., Jorba, J., Kew, O. M., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/596052 · Cited by 99
Self-citationArita, M., Zhu, S.-L., Yoshida, H., Yoneyama, T., Miyamura, T., & Shimizu, H. (2005) · Journal of Virology · doi:10.1128/jvi.79.20.12650-12657.2005 · Cited by 95 · cited 1×
“First, multiple independent cVDPV emergences have occurred in settings where the expected survival times for persons with PIDs are short [19, 43, 46].”
BackgroundSerial Recombination during Circulation of Type 1 Wild-Vaccine Recombinant Polioviruses in China
Liu, H.-M., Zheng, D.-P., Zhang, L.-B., Oberste, M. S., Kew, O. M., & Pallansch, M. A. (2003) · Journal of Virology · doi:10.1128/jvi.77.20.10994-11005.2003 · Cited by 88
Self-citationVaccine-Derived Poliomyelitis 12 Years after Infection in Minnesota
DeVries, A. S., Harper, J., Murray, A., Lexau, C., Bahta, L., Christensen, J., Cebelinski, E., Fuller, S., Kline, S., Wallace, G. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008677 · Cited by 88
Self-citationAn Outbreak of Poliomyelitis Caused by Type 1 Vaccine‐Derived Poliovirus in China
Liang, X., Zhang, Y., Xu, W., Wen, N., Zuo, S., Lee, L. A., & Yu, J. (2006) · The Journal of Infectious Diseases · doi:10.1086/506359 · Cited by 87
Neurovirulent Vaccine-Derived Polioviruses in Sewage from Highly Immune Populations
Shulman, L. M., Manor, Y., Sofer, D., Handsher, R., Swartz, T. A., Delpeyroux, F., & Mendelson, E. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000069 · Cited by 77
A Large Vaccine‐Derived Poliovirus Outbreak on Madura Island—Indonesia, 2005
Estívariz, C. F., Watkins, M. A., Handoko, D., Rusipah, R., Deshpande, J., Rana, B. J., Irawan, E., Widhiastuti, D., Pallansch, M. A., Thapa, A., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/525049 · Cited by 77
Vaccine-derived poliovirus from long term excretors and the end game of polio eradication
Martín, J. E.-S. (2006) · Biologicals · doi:10.1016/j.biologicals.2006.02.005 · Cited by 74
Korotkova, E. A., Park, R., Cherkasova, E. A., Lipskaya, G. Y., Chumakov, K. M., Feldman, E. V., Kew, O. M., & Agol, V. I. (2003) · Journal of Virology · doi:10.1128/jvi.77.23.12460-12465.2003 · Cited by 73 · cited 1×
“small communities with gaps in OPV coverage [4, 26, 33, 77, 78], and still others appear to indicate more-prolonged circulation (Table 3) or additional cVDPV emergences in outbreak settings”
BackgroundSelf-citationIsolation of recombinant type 2 vaccine-derived poliovirus (VDPV) from a Nigerian child
Adu, F., Iber, J. C., Bukbuk, D. N., Gumede, N., Yang, S.-J., Jorba, J. C., Campagnoli, R. P., Sule, W. F., Yang, C.-F., Burns, C. C., et al. (2007) · Virus Research · doi:10.1016/j.virusres.2007.03.009 · Cited by 70
Self-citationEstimating the Extent of Vaccine-Derived Poliovirus Infection
Wringe, A., Fine, P. E. M., Sutter, R. W., & Kew, O. M. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003433 · Cited by 68
Self-citationLi, L., Ivanova, O., Driss, N., Tiongco-Recto, M., da Silva, R., Shahmahmoodi, S., Sazzad, H. M. S., Mach, O., Kahn, A.-L., & Sutter, R. W. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu065 · Cited by 63 · cited 7×
“Persons with primary immunodeficiency disorders (PIDs; ie, B-cell defects in antibody production) are at much higher risk (by approximately 3000-fold) of VAPP [1, 4, 15], but VAPP is rare even in this group [11, 16].”
BackgroundInfluentialSelf-citationIn Vitro Antiviral Activity of V-073 against Polioviruses
Oberste, M. S., Moore, D. D., Anderson, B. C., Pallansch, M. A., Pevear, D. C., & Collett, M. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00671-09 · Cited by 63
Hara, M., Saito, Y., Komatsu, T., Kodama, H., Abo, W., Chiba, S., & Nakao, T. (1981) · Microbiology and Immunology · doi:10.1111/j.1348-0421.1981.tb00095.x · Cited by 56
Roivainen, M., Blomqvist, S., Al‐Hello, H., Paananen, A., Delpeyroux, F., Kuusi, M., & Hovi, T. (2010) · Eurosurveillance · doi:10.2807/ese.15.19.19566-en · Cited by 54
Vaccine-associated Paralytic Poliomyelitis in Immunodeficient Children, Iran, 1995–2008
Shahmahmoodi, S., Mamishi, S., Aghamohammadi, A., Aghazadeh, N., Tabatabaie, H., Gooya, M. M., Zahraei, S. M., Mousavi, T., Yousefi, M., Farrokhi, K., et al. (2010) · Emerging infectious diseases · doi:10.3201/eid1607.091606 · Cited by 49
Identification of vaccine-derived polioviruses using dual-stage real-time RT-PCR
Kilpatrick, D. R., Ching, K., Iber, J., Chen, Q., Yang, S.-J., De, L., Williams, A. J., Mandelbaum, M., Sun, H., Oberste, M. S., et al. (2014) · Journal of Virological Methods · doi:10.1016/j.jviromet.2013.11.017 · Cited by 45
Self-citationYoneyama, T., Hagiwara, A., Hara, M., & Shimojo, H. (1982) · Infection and Immunity · doi:10.1128/iai.37.1.46-53.1982 · Cited by 45
Hidalgo, S., Erro, M. G., Cisterna, D., & Freire, M. C. (2003) · Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000069792.60744.5b · Cited by 44
Shahmahmoodi, S., Parvaneh, N., Burns, C. C., Asghar, H., Mamishi, S., Tabatabaie, H., Chen, Q., Teimourian, S., Gooya, M. M., Esteghamati, A., et al. (2008) · Virus Research · doi:10.1016/j.virusres.2008.07.006 · Cited by 44
Self-citationPoliovirus Vaccine Shedding among Persons with HIV in Abidjan, Cote d’Ivoire
Hennessey, K. A., Lago, H., Diomande, F., Akoua‐Koffi, C., Caceres, V. M., Pallansch, M. A., Kew, O. M., Nolan, M., & Zuber, P. L. F. (2005) · The Journal of Infectious Diseases · doi:10.1086/498166 · Cited by 39 · cited 1×
“Human immunodeficiency virus (HIV) infection, which predominantly affects T cells, does not appear to elevate the risk of iVDPV infections [73, 74].”
BackgroundSelf-citationUpdate on vaccine-derived polioviruses - worldwide, July 2012-December 2013.
Diop, O. M., Burns, C. C., Wassilak, S. G. F., & Kew, O. M. (2014) · PubMed Central · Cited by 39
Self-citationIsolation of vaccine-derived polioviruses in the Slovak Republic
Cernakova, B., Sobotová, Z., Rovný, I., Blahova, S., Roivainen, M., & Hovi, T. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-1331-9 · Cited by 36
de Silva, R., Gunasena, S., Ratnayake, D., Wickremesinghe, G. D., Kumarasiri, C., Pushpakumara, B. A. W., Deshpande, J. M., Kahn, A.-L., & Sutter, R. W. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.035 · Cited by 35
Self-citationProlonged faecal excretion of poliovirus in a nurse with common variable hypogammaglobulinaemia
Misbah, S. A., Lawrence, P. A., Kurtz, J. B., & Chapel, H. M. (1991) · Postgraduate Medical Journal · doi:10.1136/pgmj.67.785.301 · Cited by 35
Emergence of Vaccine-derived Polioviruses, Democratic Republic of Congo, 2004–2011
Gumede, N., Lentsoane, O., Burns, C. C., Pallansch, M. A., de Gourville, E. M., Riziki, Y., Muyembe-Tamfum, J. J., Puren, A. J., Schoub, B. D., & Venter, M. (2013) · Emerging infectious diseases · doi:10.3201/eid1910.130028 · Cited by 35
Self-citationLabadie, K., Pelletier, I., Saulnier, A., Martín, J. E.-S., & Colbère-Garapin, F. (2003) · Virology · doi:10.1016/j.virol.2003.09.005 · Cited by 34
Characteristics of poliovirus strains from long-term excretors with primary immunodeficiencies.
Minor, P. D. (2001) · PubMed · Cited by 31
Vaccine-associated paralytic poliomyelitis in a patient with MHC class II deficiency
Parvaneh, N., Shahmahmoudi, S., Hamideh, T., Zahraei, S. M., Mousavi, T., Esteghamati, A., Gooya, M. M., Mamishi, S., Nategh, R., & Kew, O. M. (2007) · Journal of Clinical Virology · doi:10.1016/j.jcv.2007.04.002 · Cited by 30
Self-citationKhetsuriani, N., Helfand, R. F., Pallansch, M. A., Kew, O. M., Fowlkes, A., Oberste, M. S., Tukei, P. M., Muli, J., Makokha, E. P., & Gary, H. E. (2009) · BMC Infectious Diseases · doi:10.1186/1471-2334-9-136 · Cited by 30
Self-citationYan, D., Li, L., Zhu, S., Zhang, Y., An, J., Wang, D., Wen, N., Jorba, J. C., Liu, W. Y., Zhong, G., et al. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00712-10 · Cited by 28
Self-citationHighly Divergent Type 2 and 3 Vaccine-Derived Polioviruses Isolated from Sewage in Tallinn, Estonia
Al‐Hello, H., Jorba, J. C., Blomqvist, S., Raud, R., Kew, O. M., & Roivainen, M. (2013) · Journal of Virology · doi:10.1128/jvi.01174-13 · Cited by 22
Self-citationImmunodeficiency-associated Vaccine-Derived Poliovirus Type 3 in Infant, South Africa, 2011
Gumede, N., Muthambi, V., & Schoub, B. D. (2012) · Emerging infectious diseases · doi:10.3201/eid1806.120037 · Cited by 21
The Final Phase of Polio Eradication: New Vaccines and Complex Choices
Cochi, S. L., & Linkins, R. W. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir727 · Cited by 20
Hovi, T., Paananen, A., Blomqvist, S., Savolainen‐Kopra, C., Al‐Hello, H., Smura, T., Shimizu, H., Naďová, K., Sobotová, Z., Gavrilin, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066849 · Cited by 18
Cited by
Adaptive immunity to SARS-CoV-2 and COVID-19
Sette, A., & Crotty, S. (2021) · Cell · doi:10.1016/j.cell.2021.01.007 · Cited by 1,860
Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence
Yeh, M. T., Bujaki, E., Dolan, P. T., Smith, M., Wahid, R., Konz, J., Weiner, A. J., Bandyopadhyay, A. S., Van Damme, P., De Coster, I., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.003 · Cited by 221
Update on Vaccine-Derived Polioviruses-Worldwide, January 2017–June 2018
Jorba, J., Diop, O. M., Iber, J., Henderson, E., Zhao, K., Sutter, R. W., Wassilak, S. G. F., & Burns, C. C. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6742a5 · Cited by 197
Self-citationDe Coster, I., Leroux-Roels, I., Bandyopadhyay, A. S., Gast, C., Withanage, K., Steenackers, K., De Smedt, P., Aerssens, A., Leroux-Roels, G., Oberste, M. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32541-1 · Cited by 86
Sáez-Llorens, X., Bandyopadhyay, A. S., Gast, C., Leon, T. D., DeAntonio, R., Jimeno, J., Caballero, M. I., Aguirre, G., Oberste, M. S., Weldon, W. C., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32540-x · Cited by 81
Metadata
- Authors
- Burns, C. C., Diop, O. M., Sutter, R. W., & Kew, O. M.
- Venue
- Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-10-14
- Volume
- 210
- Issue
- suppl 1
- Pages
- S283-S293
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2097965467
- Cited by
- 309
- References
- 69
- FWCI
- 20.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.